By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

Key Statistics

Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO


UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient


Company News
The Medicines Company (MDCO) Announces Participation At 2015 European Society of Cardiology Congress In London 8/24/2015 7:02:26 AM
The Medicines Company (MDCO) Reports Second-Quarter And First-Half 2015 Financial Results 7/29/2015 10:59:08 AM
The Medicines Company (MDCO) To Announce Second Quarter Financial Results On Wednesday July 29, 2015 7/13/2015 10:26:46 AM
The Medicines Company (MDCO) Authorizes Generic Launch of ANGIOMAX (Bivalirudin) 7/9/2015 7:36:28 AM
Federal Circuit Rules Against The Medicines Company (MDCO) In Angiomax (bivalirudin) Patent Litigation 7/6/2015 11:25:37 AM
The Medicines Company (MDCO) May Sell European Business As Management Focuses Inward 6/26/2015 8:33:32 AM
FDA Approves The Medicines Company (MDCO)'s Blood Clot Drug KENGREAL 6/23/2015 7:28:44 AM
The Medicines Company (MDCO) To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216 6/1/2015 1:45:15 PM
The Medicines Company (MDCO) Announces Results Of Phase 1 Study For Novel Investigational Intravenous Anesthetic, ABP-700 6/1/2015 11:10:58 AM
The Medicines Company (MDCO) Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients 5/26/2015 10:53:34 AM